Gabapentin Tablet
Product Images NDC 71205-514

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-514). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-514-60 (Gabapentin 800mg 30tab)

This is a description of a medication called Gabapentin 800mg. It comes in a 90 tablet package and its main ingredient is gabapentin, USP. It has a white to off-white color, is capsule-shaped and is scored, some tablets are debossed with “SG" on one side and 178" on the other side with bisect line. Gabapentin is packaged by Proficient Rx LP and distributed by ScieGen Pharmaceuticals, Inc. Patients who take this medication should be provided with a medication guide. This medication should be kept at a temperature of between 20°C and 25°C, and out of the reach of children. The lot number is 00000, and the expiration date is 000000.*

FDA Label Image

Figure 1 (Image 01)

This is a chart displaying the mean pain score of a study. It compares the pain scores of a placebo group and a group taking gabapentin at 3600 mg/day, in both a fixed dose period and a titration period. The chart shows baseline data and data collected over the course of several weeks.*

FDA Label Image

Figure 2 (Image 02)

This is a graph showing the results of a study with a 4-week fixed dose period on the effect of Gabapentin to reduce pain score compared to a Placebo. The Gabapentin groups were given a dose of either 1800mg/day or 2400mg/day. The X-axis shows the weeks and the Y-axis shows the mean pain score.*

FDA Label Image

Figure 3 (Image 03)

FDA Label Image

Image-04 (Image 04)

FDA Label Image

Gabapentin Structural Formula (Image 05)

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.